Safety and Effectiveness Study of Combo Bio-engineered Sirolimus Eluting Stent

PHASE2CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

July 31, 2011

Study Completion Date

September 30, 2015

Conditions
Coronary Artery Lesions
Interventions
DEVICE

coronary stenting

Balloon dilatation of obstructive coronary artery disease with deployment of a metallic stent to scaffold the dilated lesion; stent incorporating sustained release of anti-proliferative agent to control neointimal proliferation and reocclusion; test device incorporates affinity surface for circulating EPCs

Trial Locations (1)

2300

John Hunter Hospital, Newcastle

Sponsors

Lead Sponsor

All Listed Sponsors
lead

OrbusNeich

INDUSTRY

NCT00967902 - Safety and Effectiveness Study of Combo Bio-engineered Sirolimus Eluting Stent | Biotech Hunter | Biotech Hunter